List of Excipients in Branded Drug MODAFINIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	CELLULOSE, MICROCRYSTALLINE
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	CROSCARMELLOSE SODIUM
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	LACTOSE MONOHYDRATE
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	MAGNESIUM STEARATE

Generic Drugs Containing MODAFINIL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	modafinil	0378-5573	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Mylan Pharmaceuticals Inc	modafinil	0378-5573	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	modafinil	0378-5573	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	modafinil	0378-5573	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in MODAFINIL?

# Of NDCs	Excipient
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
20	CELLULOSE, MICROCRYSTALLINE
39	CROSCARMELLOSE SODIUM

Modafinil Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Modafinil is a mature, genericized CNS drug with limited value in commodity immediate-release tablets and stronger opportunity in differentiated delivery systems. The most viable excipient strategies target dose flexibility, tablet performance, swallowability, taste, adherence, lactose avoidance, and controlled release. New products must preserve modafinil dissolution and exposure while demonstrating FDA bioequivalence or securing an appropriate 505(b)(2) pathway.

What is the commercial status of modafinil?

Modafinil is an oral wakefulness-promoting drug marketed in the United States as Provigil and by multiple generic manufacturers. FDA-approved indications are narcolepsy, obstructive sleep apnea-associated excessive sleepiness, and shift work sleep disorder. Standard tablet strengths are 100 mg and 200 mg.[1]

Commercial attribute	Modafinil position
Active ingredient	Modafinil, racemic 2-[(diphenylmethyl)sulfinyl]acetamide
Reference product	Provigil tablets
Original sponsor	Cephalon
Current market	Multiple generic immediate-release tablets
FDA dosage forms	Oral tablets
Common strengths	100 mg and 200 mg
Core U.S. drug exclusivity	Expired
Orange Book relevance	Historical patents and any currently listed product patents must be checked by product and edition
Biosimilar pathway	Not applicable; modafinil is a small molecule
Primary commercial risk	Price competition in conventional tablets
Primary opportunity	Formulation differentiation and specialty distribution

Modafinil has a relatively long effective duration, with an elimination half-life of approximately 15 hours in healthy adults. Its pharmacokinetics and clinical use create a commercial case for products that improve morning administration, dose adjustment, swallowing, and adherence rather than simply increasing strength.[1]

What excipients are used in Provigil and generic modafinil tablets?

Reference and generic modafinil products use conventional solid-dose excipients. Formulations vary by manufacturer and market.

Typical excipient classes include:

Excipient class	Representative materials	Commercial function
Diluent	Lactose monohydrate, starch	Tablet mass and manufacturability
Binder	Povidone, pregelatinized starch	Granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Tablet breakup and dissolution
Glidant	Colloidal silicon dioxide, talc	Powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Coating system	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Identification, protection, swallowability
Solubilization aid	Surfactants or wetting agents	Dissolution improvement where needed
Taste-masking system	Polymer film, ion-exchange resin, lipid barrier	Orally disintegrating and chewable products

The reference product's inactive ingredients have included lactose, starch-based materials, croscarmellose sodium, povidone, magnesium stearate, and talc, although the exact list should be tied to the applicable FDA labeling version.[1] Generic labels differ. That variation creates an opportunity for products designed around excipient exclusions, patient tolerability, or manufacturing efficiency.

How should an excipient strategy address modafinil’s physicochemical profile?

Modafinil is a low-dose-to-moderate-dose crystalline small molecule with limited aqueous solubility and a dissolution-sensitive oral product profile. At a 200 mg dose, the tablet contains enough active ingredient for powder flow, content uniformity, compression, and dissolution to become material formulation issues.

A development strategy should prioritize:

1. Rapid and reproducible disintegration.
2. Consistent dissolution across physiological pH conditions.
3. Low sensitivity to compression force and lubricant overmixing.
4. Robust content uniformity at the 100 mg strength.
5. Manufacturing compatibility with direct compression or low-shear granulation.
6. Excipient selection that does not materially alter exposure or food-related performance.

Hydrophilic fillers and superdisintegrants can improve tablet breakup, but excessive hydrophobic lubricant or overcompression can slow dissolution. Particle-size distribution, crystal form, milling, and blending order may have as much commercial importance as the nominal excipient list.

Which excipients can improve dissolution?

Potential approaches include:

• Croscarmellose sodium or crospovidone for rapid liquid uptake and breakup.
• Colloidal silicon dioxide to improve powder flow and reduce segregation.
• Wetting agents at low levels where dissolution testing supports their use.
• Spray-dried or co-processed excipient systems for direct compression.
• Amorphous or particle-engineered modafinil where stability and regulatory controls are adequate.
• Solid-dispersion or lipid-based approaches for 505(b)(2) products with a clinically meaningful performance benefit.

The commercial choice depends on whether the formulation is intended to be an ANDA generic, a reformulated prescription product, or a consumer-facing specialty product. A conventional generic formulation should avoid unnecessary complexity. A differentiated formulation can justify higher development cost only when it creates a defensible clinical, regulatory, or commercial advantage.

What excipient opportunities exist for modafinil formulations?

Lactose-free and excipient-restricted tablets

Lactose-free products can target patients with lactose intolerance, dietary restrictions, or pharmacy systems that prefer simplified inactive-ingredient profiles. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and starch-based systems can replace lactose, subject to dissolution and compressibility testing.

The commercial advantage is moderate. Lactose-free positioning is easy to communicate but is unlikely to support strong pricing unless combined with a more useful attribute such as an orally disintegrating tablet, smaller tablet size, or pediatric suitability.

Orally disintegrating tablets

An orally disintegrating tablet is one of the stronger formulation opportunities. It could address:

• Patients with dysphagia.
• Patients who need administration without water.
• Shift workers seeking convenient dosing.
• Institutional or emergency-use settings.
• Patients who resist swallowing conventional tablets.

Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, and taste-masking polymers are relevant excipient tools. Modafinil has a bitter or unpleasant taste profile, so a true orally disintegrating product requires taste masking rather than simple rapid disintegration.

A successful ODT would need to balance:

• Fast disintegration.
• Acceptable mouthfeel.
• Low friability.
• Adequate mechanical strength.
• Taste control.
• Packaging protection against moisture.
• Comparable systemic exposure.

Unit-dose blister packaging may provide a stronger commercial proposition than bottles because ODTs are more vulnerable to mechanical damage and moisture.

Chewable or orally dispersible products

Chewable modafinil could support patients unable to swallow tablets, but taste masking becomes more difficult because the drug remains in the mouth longer. Polymer coating, lipid coating, cyclodextrin complexation, ion-exchange resin binding, or multiparticulate encapsulation could be evaluated.

The regulatory burden may exceed that of an ODT because palatability, dose uniformity, and accidental repeat dosing become more important. The product may also be viewed as attractive for misuse or nonmedical use, requiring careful packaging and market positioning.

Pediatric formulations

Modafinil is not broadly approved as a pediatric wakefulness medicine in the United States. A pediatric formulation would therefore raise clinical, regulatory, and safety issues beyond excipient selection. A liquid, powder-for-suspension, mini-tablet, or dispersible tablet could be developed, but the commercial market would depend on an approved pediatric indication or a legally supportable 505(b)(2) strategy.

Excipient priorities would include:

• Low-sugar or sugar-free design.
• Preservative selection.
• Dose flexibility.
• Uniform redispersion.
• Reduced alcohol and propylene glycol exposure.
• Taste masking.
• Stability after opening.

Pediatric use is a longer-term opportunity, not an immediate generic substitution strategy.

What formulation patents could protect a modafinil product?

A new excipient combination alone usually provides weak protection if it is an obvious substitution for known tablet ingredients. Stronger patent positions generally require a defined technical effect, such as:

• A specific dissolution profile.
• Improved bioavailability or reduced food effect.
• A stable amorphous form.
• A controlled-release profile.
• A taste-masked multiparticulate system.
• A moisture-resistant ODT.
• A specific particle-size or crystal-form distribution.
• A manufacturing process that produces a reproducible solid form.
• A clinically meaningful reduction in dose variability.

Which patent claims are commercially stronger?

Claim type	Typical strength	Commercial value
Broad excipient substitution	Low	Limited
Specific excipient ratios	Low to moderate	Useful if tied to performance
Dissolution-profile claims	Moderate	Stronger if reproducible and clinically relevant
Taste-masked dosage form	Moderate	Potential value for ODT or chewable products
Controlled-release formulation	Moderate to strong	Can support product differentiation
Stable polymorph or amorphous form	Moderate to strong	Depends on freedom-to-operate and prior art
Manufacturing process	Moderate	Valuable when difficult to design around
Method-of-use claim	Variable	Depends on indication and patent term

A formulation patent should be supported by comparative data against Provigil and representative generics. Useful evidence includes dissolution under multiple pH conditions, fed and fasted pharmacokinetics, accelerated stability, tablet robustness, taste scores, and manufacturing-scale reproducibility.

When does modafinil lose exclusivity, and what is the generic entry risk?

Modafinil’s principal U.S. exclusivity period ended years ago. Generic products are established, and conventional immediate-release tablets face high price pressure. The commercial question is no longer whether generic entry will occur. It is whether a differentiated product can avoid direct price comparison.

The original Provigil patent estate included composition and formulation-related rights associated with Cephalon. Historical patent disputes and Paragraph IV challenges involved major generic companies, including Teva, Mylan, Ranbaxy, and Apotex. Settlement agreements permitted generic entry before the full expiration of all asserted rights. The Federal Trade Commission later challenged aspects of Cephalon’s settlement strategy and obtained relief related to alleged reverse-payment conduct.[2][3]

Issue	Current commercial implication
Core molecule	No meaningful exclusivity barrier
Conventional tablet	High generic competition
Formulation patent	Potential barrier only if valid, enforceable, and difficult to design around
ODT or taste-masked product	Potentially differentiated, but patent scope must be narrow and technically supported
Controlled release	Higher opportunity, higher clinical and regulatory cost
Paragraph IV risk	Relevant for any new listed product patent
Biosimilar risk	None
Authorized generic risk	Possible where an innovator or licensee controls a competing product

A new modafinil product with Orange Book-listed patents could attract Paragraph IV certification. The sponsor would face patent litigation risk if the product is commercially meaningful and the claims cover the proposed dosage form or method of use.

What is the FDA regulatory pathway for new modafinil formulations?

A conventional immediate-release tablet that references Provigil generally follows the ANDA pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and satisfy FDA requirements for quality, manufacturing, labeling, and stability.[4]

A materially differentiated product may require a 505(b)(2) application. This route may be appropriate for:

• Extended-release modafinil.
• An ODT with a clinically relevant performance profile.
• A new route of administration.
• A pediatric product.
• A liquid or suspension.
• A formulation with a different dosing regimen.
• A product relying partly on FDA findings for the listed drug.

The pathway affects commercial timing and intellectual-property strategy:

Product concept	Likely pathway	Development burden
Conventional 100/200 mg tablet	ANDA	Low to moderate
Lactose-free tablet	ANDA	Low to moderate
ODT with same strength and exposure	ANDA or 505(b)(2), depending on design	Moderate
Chewable product	Often 505(b)(2) if clinically distinct	Moderate to high
Extended-release tablet	505(b)(2)	High
Pediatric liquid	505(b)(2) or supplemental clinical strategy	High
New indication	505(b)(2) or separate clinical program	High

FDA labeling also requires attention to modafinil’s interaction profile. Modafinil induces CYP3A enzymes and can reduce exposure to certain hormonal contraceptives. It inhibits CYP2C19 and can affect exposure to drugs metabolized through that pathway.[1] Excipients do not remove these pharmacologic limitations.

What manufacturing and intellectual-property barriers affect modafinil?

The most important manufacturing barriers are control of particle size, blend uniformity, compression behavior, dissolution, and solid-state stability. These factors can create practical differentiation even when the excipient list appears ordinary.

Potential process know-how includes:

• Controlled milling and particle classification.
• Wet granulation endpoint control.
• Low-shear blending to avoid segregation.
• Lubrication-time control.
• Coating uniformity.
• Moisture-protective packaging.
• Continuous manufacturing for dose and blend consistency.
• In-process dissolution or near-infrared monitoring.

A company can protect these capabilities through process patents, trade secrets, supplier qualification, and validated control strategies. Trade-secret protection is particularly relevant where the final product does not reveal the critical manufacturing parameters.

Geographic coverage should be assessed separately. U.S. freedom to operate does not establish freedom to operate in Europe, Canada, Japan, India, or emerging markets. Patent term, compulsory licensing rules, local Orange Book equivalents, data exclusivity, and local generic-registration requirements differ by jurisdiction.

Which companies are challenging or competing with modafinil products?

The competitive landscape is fragmented. Generic manufacturers compete primarily on price, supply reliability, wholesaler access, and procurement contracts. A differentiated entrant would compete against:

• Generic modafinil tablets.
• Armodafinil products such as Nuvigil and generic armodafinil.
• Methylphenidate and amphetamine products for wakefulness-related indications.
• Sodium oxybate products in narcolepsy.
• Emerging wake-promoting agents such as solriamfetol and pitolisant.

How does modafinil compare with armodafinil?

Armodafinil is the R-enantiomer of modafinil and has separate product and patent histories. It may provide a competing platform for controlled-release, ODT, or specialty formulations.

Factor	Modafinil	Armodafinil
Chemical form	Racemic mixture	R-enantiomer
Major brand	Provigil	Nuvigil
Standard strengths	100 mg, 200 mg	50 mg, 150 mg, ได้? 250 mg
Generic competition	Extensive	Extensive, but historically later
Formulation opportunity	ODT, controlled release, taste masking	Dose optimization, modified release
Patent strategy	Formulation and process claims	Formulation, crystal, and method claims

Modafinil has broader generic availability and a lower-cost API position. Armodafinil may offer a better platform for dose or release-profile differentiation, but its commercial market is also mature.

What licensing deals and settlement issues affect modafinil?

The major historical licensing and litigation issues centered on Cephalon’s Provigil patent estate and generic settlements. The FTC’s action against Cephalon focused on agreements that delayed generic entry and involved payments or other consideration.[2] Those agreements are primarily historical and do not create a current market barrier for ordinary modafinil tablets.

For a new formulation, licensing value would arise from:

• Access to a patented ODT technology.
• Taste-masking or multiparticulate know-how.
• A protected solid form.
• A 505(b)(2) regulatory package.
• A specialty pharmacy or institutional distribution channel.
• A manufacturing platform with demonstrated scale-up.

A license is commercially attractive only if it produces a defensible advantage over low-cost generic tablets. A broad excipient patent with weak enforceability is unlikely to justify a substantial royalty.

What revenue exposure exists for a new modafinil product?

A standard generic modafinil tablet has limited revenue upside because multiple suppliers compete in a mature market. Revenue can improve through differentiated positioning:

Opportunity	Pricing potential	Market size potential	Main risk
Low-cost generic tablet	Low	High	Severe price competition
Lactose-free tablet	Low to moderate	Moderate	Easy substitution
ODT	Moderate	Moderate	Taste and stability
Chewable	Moderate	Low to moderate	Palatability and misuse concerns
Extended release	High if clinically useful	Moderate	505(b)(2) cost and clinical risk
Institutional blister format	Moderate	Moderate	Procurement pricing
Pediatric product	High if approved	Uncertain	Clinical and regulatory risk
Specialty combination product	High	Uncertain	New clinical and patent requirements

The strongest near-term business case is a low-complexity ODT or dispersible product with a clean excipient profile, reliable taste masking, and packaging optimized for shift workers and patients with swallowing limitations. Controlled release has greater theoretical value but carries a substantially higher development burden.

How strong is the patent estate for a new modafinil formulation?

The patent estate for the original molecule is commercially weak because the active ingredient is long genericized. A new formulation can have moderate protection if it demonstrates a real technical effect and uses claims that competitors cannot easily design around.

Patent strength should be scored across five dimensions:

1. Claim breadth: whether the claims cover only one ratio or a meaningful class of formulations.
2. Technical effect: whether the formulation produces a measurable benefit.
3. Prior art: whether similar modafinil or CNS formulations already disclose the approach.
4. Detectability: whether infringement can be identified from the finished product.
5. Design-around risk: whether a competitor can switch excipients without losing performance.

A formulation patent that claims a narrow ratio of mannitol and crospovidone may be easy to avoid. A patent covering a defined taste-masked particle architecture, dissolution window, and manufacturing process can be more defensible.

Key Takeaways

• Modafinil is a mature generic market with little value in an undifferentiated immediate-release tablet.
• Excipient opportunities are strongest in ODT, dispersible, taste-masked, lactose-free, and controlled-release products.
• Taste masking is essential for any orally disintegrating or chewable formulation.
• Rapid dissolution, content uniformity, and lubricant control are central formulation-development risks.
• A conventional generic usually follows the ANDA pathway; materially different products may require 505(b)(2).
• The original Provigil patent and settlement disputes are historical. Current value depends on new formulation claims, process know-how, and commercial differentiation.
• Modafinil has no biosimilar pathway because it is a small-molecule drug.
• The most practical near-term opportunity is a patient-focused ODT or dispersible product supported by a clean excipient profile and strong packaging.
• Controlled-release and pediatric products may generate higher pricing but require greater clinical and regulatory investment.

FAQs

Can mannitol replace lactose in a modafinil tablet?

Yes. Mannitol can function as a diluent and improve mouthfeel, particularly in ODTs. The formulation must be optimized for hardness, friability, dissolution, moisture sensitivity, and content uniformity.

Is a modafinil ODT likely to require a new clinical trial?

Not necessarily. If the ODT produces comparable exposure and the proposed labeling remains within the reference product’s approved use, an ANDA may be possible. A 505(b)(2) application may be required if the dosage form, dosing conditions, or clinical use is materially different.

Are modafinil excipient patents likely to block generic competition?

Only if the claims are valid, enforceable, listed where applicable, and difficult to design around. Broad claims to routine diluents or disintegrants generally provide limited protection.

Can an extended-release modafinil product command premium pricing?

Potentially, but the product would need to demonstrate a meaningful benefit, such as fewer daily doses, smoother exposure, reduced late-day adverse effects, or improved adherence. The development pathway is materially more expensive than a standard ANDA.

Does modafinil have biosimilar competition?

No. Modafinil is a chemically synthesized small molecule, so competing products are generics or reformulated products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Provigil (modafinil) tablets: Prescribing information. FDA.

2. Federal Trade Commission. (2015). In the matter of Cephalon, Inc., a corporation: Decision and order. FTC.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.